Johnson & Johnson Building Case With New Patient Survival Data For Darzalex In Multiple Myeloma

  • Janssen Pharmaceutical, a unit of Johnson & Johnson JNJannounced overall survival (OS) results from the Phase 3 MAIA study evaluating the Darzalex combo in patients with newly diagnosed multiple myeloma.
  • After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed.
  • Adding Darzalex (daratumumab) to Bristol-Myers Squibb Co’s BMY Revlimid (lenalidomide) and steroid dexamethasone (Rd) could slash the risk of death by 32% in newly diagnosed multiple myeloma patients ineligible to receive stem cell transplants.
  • Data were reported at the European Hematology Association’s virtual congress.
  • The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement.
  • Highlights from longer-term follow-up analysis:
    • The overall survival rate of 66% with Darzalex-Rd (D-Rd) vs. 53% with Rd.
    • The progression-free survival rate of 53% with D-Rd vs. 29% with Rd.
    • Median time to subsequent treatment was not reached with D-Rd vs. 42.4 months with Rd.
    • The updated overall response rate of 93% with D-Rd vs. 82% with Rd.
  • Price Action: JNJ shares closed at $164.96 on Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefsmultiple myeloma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!